Immunosuppressive therapy. 2.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002699:Chlorambucil / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000187:drug effects; D005921:Glomerulonephritis / Q000188:drug therapy; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D009369:Neoplasms / Q000139:chemically induced; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011247:Pregnancy
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D002699:Chlorambucil; D003520:Cyclophosphamide; D001379:Azathioprine